THIRD HARMONIC BIO INC (THRD)
US88427A1079 - Common Stock
Taking everything into account, THRD scores 3 out of 10 in our fundamental rating. THRD was compared to 191 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for THRD as it has an excellent financial health rating, but there are worries on the profitability. THRD is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year THRD has reported negative net income.
In the past year THRD has reported a negative cash flow from operations.
1.2 Ratios
The Return On Assets of THRD (-12.87%) is better than 68.48% of its industry peers.
The Return On Equity of THRD (-13.29%) is better than 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.87% | ||
| ROE | -13.29% | ||
| ROIC | N/A |
ROA(3y)-15.26%
ROA(5y)N/A
ROE(3y)-15.86%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
THRD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
Compared to 1 year ago, THRD has more shares outstanding
THRD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
THRD has an Altman-Z score of 30.87. This indicates that THRD is financially healthy and has little risk of bankruptcy at the moment.
THRD has a Altman-Z score of 30.87. This is amongst the best in the industry. THRD outperforms 94.57% of its industry peers.
THRD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 30.87 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 42.50 indicates that THRD has no problem at all paying its short term obligations.
THRD has a better Current ratio (42.50) than 99.46% of its industry peers.
A Quick Ratio of 42.50 indicates that THRD has no problem at all paying its short term obligations.
THRD's Quick ratio of 42.50 is amongst the best of the industry. THRD outperforms 99.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 42.5 | ||
| Quick Ratio | 42.5 |
3. Growth
3.1 Past
THRD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.79%, which is quite good.
EPS 1Y (TTM)15.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-73.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
THRD is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -13.31% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-17.75%
EPS Next 2Y-26.34%
EPS Next 3Y-30.08%
EPS Next 5Y-13.31%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for THRD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for THRD. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
THRD's earnings are expected to decrease with -30.08% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.34%
EPS Next 3Y-30.08%
5. Dividend
5.1 Amount
THRD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
THIRD HARMONIC BIO INC
NASDAQ:THRD (1/3/2025, 8:05:49 PM)
After market: 11.03 0 (0%)11.03
-0.01 (-0.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners82.77%
Inst Owner Change9.37%
Ins Owners3.49%
Ins Owner Change-12.38%
Market Cap497.01M
Analysts81.67
Price Target19.38 (75.7%)
Short Float %10.39%
Short Ratio15.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.31%
Min EPS beat(2)-8.2%
Max EPS beat(2)5.59%
EPS beat(4)3
Avg EPS beat(4)20.04%
Min EPS beat(4)-8.2%
Max EPS beat(4)46.24%
EPS beat(8)6
Avg EPS beat(8)20.24%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.43%
EPS NY rev (1m)0%
EPS NY rev (3m)1%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.69 | ||
| P/tB | 1.69 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.96
EYN/A
EPS(NY)-1.52
Fwd EYN/A
FCF(TTM)-0.64
FCFYN/A
OCF(TTM)-0.64
OCFYN/A
SpS0
BVpS6.54
TBVpS6.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.87% | ||
| ROE | -13.29% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-15.26%
ROA(5y)N/A
ROE(3y)-15.86%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 1.96% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 42.5 | ||
| Quick Ratio | 42.5 | ||
| Altman-Z | 30.87 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-73.68%
EPS Next Y-17.75%
EPS Next 2Y-26.34%
EPS Next 3Y-30.08%
EPS Next 5Y-13.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-12.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.67%
EBIT Next 3Y-25.88%
EBIT Next 5Y-26.56%
FCF growth 1Y41.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.51%
OCF growth 3YN/A
OCF growth 5YN/A